MRK
NYSE · Pharmaceuticals
Merck & Co. Inc.
$128.63
+0.30 (+0.23%)
MRK News30 articles
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Tech Gains Mask Narrow Market as Jobs Report Looms
Stocks closed higher this week, but tech-led gains masked a narrow rally. Investors now await the July jobs report, which could influence Fed rate hike expectations.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
Agenus Shares Surge 83% on $340M Financing for Key Colon Cancer Trial
Agenus shares surged 83% on news of up to $340M financing for a pivotal colon cancer trial, but three-quarters of that amount hinges on investor warrants.
Pfizer's 7% Dividend Yield Attracts Income Seekers Amid Market Turmoil
Pfizer (PFE) added 1.28% in post-market trading Monday, outperforming the broader market as investors rotated into defensive stocks amid geopolitical tensions and a tech selloff.
Agenus Stock Surges 59% on $340 Million Funding Deal
Agenus (AGEN) shares jumped 59% premarket on a $340 million financing deal, though full exercise of warrants could nearly triple the share count. The funds support a strategic pivot to a major colon cancer trial.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Dividend ETFs Face Headwinds as Oil, Rates, and AI Shifts Fragment Markets
Dividend ETFs are under pressure as oil prices surge and Treasury yields climb, with SCHD and VYM trailing the S&P 500. Investors weigh concentration risks, sector exposure, and payout stability.
Pfizer's Dividend Sustainability in Focus After HSBC Downgrade
Pfizer shares slid after HSBC downgraded the stock, turning investor attention to the sustainability of its 7.3% dividend yield amid a payout ratio near 60% of adjusted EPS guidance.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.
Pfizer Gains as 7% Yield Attracts, China Trial Scrutiny Looms
Pfizer (PFE) shares climbed 2.1% on Thursday, supported by a high dividend yield, but a U.S. House committee probe into its China trial data adds uncertainty.
Abivax Shares Surge on Improved Safety Data for Ulcerative Colitis Drug
Abivax shares rallied 35.77% in Paris after updated safety data showed malignancy rates for obefazimod fell within expected ulcerative colitis background levels.
Pfizer Rebounds After Cancer Setback, Dividend Sustainability in Spotlight
Pfizer shares bounced 2.6% Friday after six straight declines, as investors weighed a dividend payout against a failed lung cancer study, an FDA win for Ibrance, and a pending CFO change.
Bio-Techne Jumps on Merck KGaA Cash Bid; Spread Signals Deal Risk
Bio-Techne shares jumped 19% on Merck KGaA's $73 cash offer, leaving a $2.83 spread as the deal awaits shareholder and regulatory approvals.
Pfizer Stock Drops as Seagen Cancer Drug Fails Key Trial
Pfizer shares slid on heavy volume after its Seagen-acquired lung cancer drug failed a Phase 3 trial, casting doubt on a key oncology growth driver ahead of Q2 results.
Pfizer Shares Dip as Key Lung Cancer Drug Fails Trial, Pressuring Growth Plans
Pfizer shares slipped 0.8% after a key lung cancer drug from its Seagen acquisition missed survival goals in a late-stage trial, intensifying pressure on growth plans.
Amazon Ousts Walmart to Top Fortune 500, Reshaping Corporate Peeking Order
Amazon has claimed the top spot on the 2026 Fortune 500, ending Walmart's 13-year run and signaling a shift in corporate power driven by e-commerce, cloud computing, and healthcare.
Amazon Ousts Walmart as Fortune 500 Leader; Regional Giants Shine
Amazon unseats Walmart as Fortune 500 No. 1, breaking a 13-year streak. Erie Insurance rises, New Jersey boasts 15 firms, and New England has over 20 companies on the list.
Dow Slips as Tech Rebound Skips Blue Chips; Focus on CPI, Energy
The Dow slipped 104 points as a tech-led rally lifted the S&P 500 and Nasdaq, but blue chips lagged. Markets now eye Wednesday's CPI data and Middle East energy risks.
SCHD's Heavy Top Holdings Raise Red Flags for Safety Seekers
SCHD's top 10 holdings now make up 43.5% of assets, raising concentration risk. With a 3.24% yield and $95.17B in assets, the fund's safety profile is under scrutiny.
J&J Shares Rise Amid Market Turmoil; Pipeline and Dividend in Focus
Johnson & Johnson shares rose 2.02% on Friday, outperforming the S&P 500, as a Los Angeles jury found the company not negligent in a talc lawsuit.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Dow Hits Record High as Oil Plunges; AI Stocks Take a Breather
The Dow Jones Industrial Average closed at a record high of 50,650.76 on Wednesday, lifted by healthcare and consumer stocks, as oil prices tumbled and AI-related shares cooled.
Tech Stocks Propel S&P 500 and Nasdaq Higher; Dow Slips on Energy and Healthcare Weakness
The Dow slipped 0.26% on Tuesday as UnitedHealth and Chevron weighed, while the S&P 500 and Nasdaq rallied on tech and AI stocks. Oil prices climbed amid geopolitical concerns.
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.
Wall Street Slips as Tech Retreats, Bond Yields Stay Elevated
U.S. stocks declined Monday as technology shares lost momentum ahead of Nvidia's earnings, while rising oil and elevated bond yields kept inflation concerns in focus.